CX3CL1 and asthma: Consistent with this result, we found that CX3CL1 expression was decreased in non-asthma-derived ASM treated with vitamin D vs. at baseline (q-value 0.011; log2 fold-change 2.3), but the findings did not hold in fatal asthma-derived ASM.